title: A dose-volume analysis of magnetic resonance imaging-aided high-dose-rate image-based interstitial brachytherapy for uterine cervical cancer.
abstract: OBJECTIVE
  To investigate the feasibility of our novel image-based high-dose-rate interstitial brachytherapy (HDR-ISBT) for uterine cervical cancer, we evaluated the dose-volume histogram (DVH) according to the recommendations of the Gynecological GEC-ESTRO Working Group for image-based intracavitary brachytherapy (ICBT).
  
  
  METHODS
  Between June 2005 and June 2007, 18 previously untreated cervical cancer patients were enrolled. We implanted magnetic resonance imaging (MRI)-available plastic applicators by our unique ambulatory technique. Total treatment doses were 30-36 Gy (6 Gy per fraction) combined with external beam radiotherapy (EBRT). Treatment plans were created based on planning computed tomography with MRI as a reference. DVHs of the high-risk clinical target volume (HR CTV), intermediate-risk CTV (IR CTV), and the bladder and rectum were calculated. Dose values were biologically normalized to equivalent doses in 2-Gy fractions (EQD(2)).
  
  
  RESULTS
  The median D90 (HR CTV) and D90 (IR CTV) per fraction were 6.8 Gy (range, 5.5-7.5) and 5.4 Gy (range, 4.2-6.3), respectively. The median V100 (HR CTV) and V100 (IR CTV) were 98.4% (range, 83-100) and 81.8% (range, 64-93.8), respectively. When the dose of EBRT was added, the median D90 and D100 of HR CTV were 80.6 Gy (range, 65.5-96.6) and 62.4 Gy (range, 49-83.2). The D(2cc) of the bladder was 62 Gy (range, 51.4-89) and of the rectum was 65.9 Gy (range, 48.9-76).
  
  
  CONCLUSIONS
  Although the targets were advanced and difficult to treat effectively by ICBT, MRI-aided image-based ISBT showed favorable results for CTV and organs at risk compared with previously reported image-based ICBT results.
authors.affiliation: Department of Radiology, National Hospital Organization Osaka National Hospital, Osaka, Japan. kyoshida@onh.go.jp
authors.forename: Ken
authors.initials: K
authors.lastname: Yoshida
authors.forename: Hideya
authors.initials: H
authors.lastname: Yamazaki
authors.forename: Tadashi
authors.initials: T
authors.lastname: Takenaka
authors.forename: Tadayuki
authors.initials: T
authors.lastname: Kotsuma
authors.forename: Mineo
authors.initials: M
authors.lastname: Yoshida
authors.forename: Seiichi
authors.initials: S
authors.lastname: Furuya
authors.forename: Eiichi
authors.initials: E
authors.lastname: Tanaka
authors.forename: Tadaaki
authors.initials: T
authors.lastname: Uegaki
authors.forename: Keiko
authors.initials: K
authors.lastname: Kuriyama
authors.forename: Hisanobu
authors.initials: H
authors.lastname: Matsumoto
authors.forename: Shigetoshi
authors.initials: S
authors.lastname: Yamada
authors.forename: Chiaki
authors.initials: C
authors.lastname: Ban
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D000553:Ambulatory Care / Q000379:methods; D001918:Brachytherapy / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D018196:Carcinoma, Adenosquamous / Q000473:pathology / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000532:radiotherapy; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053783:Magnetic Resonance Imaging, Interventional / Q000379:methods*; D008875:Middle Aged; D011879:Radiotherapy Dosage; D012007:Rectum / Q000528:radiation effects; D018709:Statistics, Nonparametric; D047368:Tumor Burden; D001743:Urinary Bladder / Q000528:radiation effects; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000532:radiotherapy*